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Fatty acid composition of the anterior cingulate cortex indicates a high 
susceptibility to lipid peroxidation in Parkinson's disease 
Abstract 
Background: Oxidative stress contributes to Parkinson's disease (PD) etiology. Although previous studies 
have focused on sources of free radical formation in brain regions affected by PD, less is known regarding 
changes in lipid composition and the implications for susceptibility to peroxidation. Objective: To assess 
fatty acid profiles from control and PD tissues that are susceptible to PD pathology but devoid of severe 
destruction. Methods: We used gas chromatography methods to assess fatty acid profiles from control (n 
= 10) and PD (n = 9) postmortem tissues. We focused on the anterior cingulate cortex (ACC), a region that 
accumulates alpha-synuclein, but does not undergo severe destruction, and compared this to the occipital 
cortex, a region that is pathologically spared. Results: Our data indicate a significant 33% increase in the 
proportion of polyunsaturated fatty acids (mol%) present in the PD ACC as compared to control ACC. 
Increases in highly unsaturated 22:5n-6 and 22:6n-3 fatty acids were particularly pronounced (109% and 
73%, respectively). Calculation of a peroxidation index (accounting for total fatty acyl double bounds) 
indicated a 44% increase in susceptibility of the PD ACC to lipid peroxidation compared to control ACC. 
Such differences were not detected in the occipital cortex from the same donors. Assessment of 
F2-isprostane levels confirmed that PD tissue lipids were more oxidized than controls. Conclusions: The 
global composition of fatty acids in the PD ACC is altered in a way that increases susceptibility to 
peroxidation in a region-specific manner. This has important implications for PD, supporting the oxidative 
stress hypothesis of PD pathogenesis. 
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BACKGROUND: Oxidative stress contributes to Parkinson’s disease (PD) etiology. 
Although previous studies have focused on sources of free radical formation in brain regions 
affected by PD, less is known regarding changes in lipid composition and the implications for 
susceptibility to peroxidation. 
OBJECTIVE: To assess fatty acid profiles from control and PD tissues that are susceptible to 
PD pathology but devoid of severe destruction. 
METHODS: We used gas chromatography methods to assess fatty acid profiles from control 
(n=10) and PD (n=9) postmortem tissues. We focused on the anterior cingulate cortex (ACC), 
a region that accumulates alpha-synuclein, but does not undergo severe destruction, and 
compared this to the occipital cortex, a region that is pathologically spared. 
RESULTS: Our data indicate a significant 33% increase in the proportion of polyunsaturated 
fatty acids (mol%) present in the PD ACC as compared to control ACC. Increases in highly 
unsaturated 22:5n-6 and 22:6n-3 fatty acids were particularly pronounced (109% and 73%, 
respectively). Calculation of a peroxidation index (accounting for total fatty acyl double 
bounds) indicated a 44% increase in susceptibility of the PD ACC to lipid peroxidation 
compared to control ACC. Such differences were not detected in the occipital cortex from the 
same donors. Assessment of F2-isprostane levels confirmed that PD tissue lipids were more 
oxidized than controls. 
CONCLUSIONS: The global composition of fatty acids in the PD ACC is altered in a way 
that increases susceptibility to peroxidation in a region-specific manner. This has important 
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Parkinson’s disease (PD) affects approximately 1-2% of the population over 65 years 
increasing to 3-5% in people over 85 years old [1,2]. The pathological hallmarks of PD 
include the loss of dopaminergic neurons in the substantia nigra pars compacta (SN) and the 
formation of Lewy bodies and Lewy neurites that are composed of aggregated alpha-
synuclein (α-syn) and other components including lipids [3,4,5]. Lewy pathologies occur 
progressively in selected neurons located in the brainstem, limbic cortices and finally the 
neocortex [3,6,7,8]. Degeneration of the SN and involvement of the amygdala occur 
preclinically with the anterior cingulate cortex (ACC) affected early after the onset of clinical 
symptoms, whereas the occipital cortex (OCC) is pathologically spared [3,6,7,8]. 
 
There is very strong evidence indicating that oxidative stress is associated with PD pathology 
[9,10,11,12]. Several studies have suggested that lipid peroxidation may represent a 
significant etiological factor and accelerator of disease progression [11,12,13,14,15]. Many 
lines of investigation have been pursued related to oxidative stress in PD, and these have 
most commonly focused on identifying the origin of free radical species, including the roles 
of tyrosine, DOPA and tyrosine hydroxylase; iron, copper and metal-rich substances, such as 
neuromelanin; dysfunctions in mitochondrial electron transport, and protein / amino acid 
radicals, for example related to α-syn Met side chains, and amino acid-metal complexes 
[16,17,18]. 
 
A selective decrease in antioxidant “defense” systems, including altered GSH metabolism, 
decreased ferritin, and changes in levels of vitamins C and E, polyphenols and coenzyme 
Q10, have also been postulated to be associated with, and to predispose towards, 
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neurodegeneration in PD [19,20,21]. It is generally thought that an imbalance between free 
radical production and antioxidant defense increases oxidative stress and thereby contributes 
to PD pathology [11,12]. This is supported by studies showing region-specific increases in 
oxidative stress in the PD brain. For example, previous studies have shown that the SN is 
subjected to oxidative stress [16,17,18,22,23,24]. Other regions that may also be affected by 
Lewy pathology albeit less severely (e.g. frontal cortex, putamen and caudate) also appear to 
be associated with oxidative stress, although this varies depending on the precise markers of 
oxidative stress / damage assessed [13,14,15,25]. Another finding replicated in several 
studies is that aggregation of α-syn is generally associated with lipid peroxidation 
[14,26,27,28,29,30]; whether this is due to a failed antioxidant action of α-syn or a 
detrimental action of α-syn / α-syn-metal complexes remains to be determined. 
 
An additional important factor that has not received as much attention relates to the global 
fatty acid composition of brain tissues and the calculated propensity of such fatty acids to 
become oxidized. This is important, as it is well known that a higher level of lipid acyl chain 
unsaturation is a very strong indicator of tissue/membrane susceptibility to peroxidation 
[31,32,33]. Indeed, the “oxidizabilities” of polyunsaturated fatty acids (PUFAs) are linearly 
dependent on the number of double bonds in the fatty acyl chains [32]. It is therefore possible 
to calculate a peroxidation index (PI) based on the number of fatty acid bisallylic double 
bonds in model systems and in animal tissues [31,33]. Furthermore, there is increasing 
evidence that a higher membrane PUFA content (i.e. higher PI) contributes to membrane 
lipid oxidation and an inverse relationship with longevity across a wide range of animal 
species [34]. Even though there may be a rationale for certain health-promoting benefits of 
specific PUFAs in the PD context [35], it is critical to understand how tissue PUFA balance 
might be altered in PD and how such changes may associate with lipid peroxidation in the 
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brain. In the present study we have addressed this issue by undertaking a detailed study of 
global fatty acid profiles in the ACC and OCC regions of healthy control and confirmed PD 
cases. We have previously shown in the same cases a significant shift in ceramide function in 
lipid membranes and signaling pathways in the PD ACC [36]. In the present study we 
calculate PI values and F2-isoprostane (F2-ISP) levels as markers of lipid peroxidation and 
reveal that the PD ACC fatty acid profile has an increased susceptibility to peroxidation as 
compared to control tissues. 
 
MATERIALS AND METHODS 
 
Materials  
Methyl-tert-butyl ether (MTBE), chloroform and methanol were HPLC grade and purchased 
from Thermo Scientific, Scoresby, VIC, Australia. Analytical grade butylated 
hydroxytoluene (BHT) and sodium hydroxide (98% minimum) were from Sigma Aldrich, 
Sydney, NSW, Australia and analytical grade ammonium acetate was from Crown Scientific, 
Moorebank, NSW, Australia. Screw thread vials (4 ml) and wide mouth vials (1.8 ml) with 
PTFE/silicone septa caps were from Grace Davison, Rowville, VIC, Australia. The fatty acid 
standard contained heneicosanoic acid (C21:0; 3.1 mM in methanol; purchased from Sigma 
Aldrich, Sydney, NSW, Australia) The F2-ISP internal standards were obtained from Cayman 
chemicals (Sapphire Bioscience, Sydney, NSW, Australia) and were dissolved in 
ispopropanol as previously described [37]. All lipid internal standards were stored at -20˚C. 
 
Human brain tissue 
Frozen brain grey matter from 10 control cases and 9 sporadic PD cases were received from 
the Sydney Brain Bank and the NSW Tissue Resource Centre. Standardized 
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clinicopathological criteria were used for diagnosis with no case or control having any 
evidence of significant neuropathology other than PD [38]. This cohort of control and PD 
tissues has been previously described in detail [36]. The control and PD groups were matched 
for both age (Con 74.7 + 2.9 y, PD 77.8 + 1.9 y, mean + SE) and postmortem interval (Con 
22.0 + 4.8 h, PD 18.4 + 2.9 h, mean + SE). Tissue pH levels were all > 6.0 and there were no 
significant differences (P > 0.05) between the control and PD groups [36]. The PD cases all 
had increased α-syn levels in the ACC whereas such an increase was not present in the 
control ACC nor in the PD OCC or control OCC [36]. The ACC Lewy body score was based 
on α-syn pathology and was measured using immunohistochemical techniques as previously 
reported [36]. In addition, the levels of SDS-soluble α-syn present in the PD ACC were 
previously quantified by western blotting as described and reported [39]. The relative optical 
density value for the SDS-soluble α-syn level in all PD ACC samples was used to assess α-
syn levels. Ethics approval was from the University of New South Wales Human Research 
Ethics Committee and the University of Wollongong Human Research Ethics Committee. 
The research has been carried out in accordance with the Declaration of Helsinki (2008) of 
the World Medical Association. All persons gave their informed consent prior to their 
inclusion in the study. 
 
Approximately 35 mg of frozen brain tissue from the ACC and OCC was pulverized over dry 
ice and two aliquots of approximately 20 and 15 mg were accurately weighed and stored at -
80°C until required for fatty acid and F2-ISP analysis, respectively. 
 
Lipid extraction  
The lipid extraction was performed as previously described in detail [40]. In brief, 
approximately 15 mg of pulverised human brain tissue was accurately weighed directly into 
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each 0.5 ml Precellys® tube (Sapphire Bioscience, Waterloo, NSW, Australia) and 
homogenised in 300 µl ice-cold methanol containing fatty acid/F2-ISP internal standards (2 µl 
/mg tissue and 10 µl /sample, respectively) and BHT (0.01% w/v), using a Precellys®24 bead 
homogeniser (Bertin Technologies; 2 x 30 sec at 6000 rpm). After transferring the 
homogenate to a 4 ml glass vial, the Precellys tube was rinsed with 162 µl methanol and 1540 
µl MTBE was added to the glass vial (final MTBE/methanol ratio 10:3, vol:vol). Following 
overnight extraction, 380 µl of 0.15M ammonium acetate was added and the organic (upper) 
phase was collected in a 4 ml vial. The original homogenate was re-extracted by addition of 
616 µl of the upper phase MTBE/methanol/0.15M ammonium acetate and combining the 
upper phase with the first extract. This lipid extract was then dried under nitrogen at 37°C 
and resuspended in chloroform/methanol (1:2, vol:vol). 
 
Analysis of fatty acid methyl esters by GC 
Fatty acids were methylated and analysed as fatty acid methyl esters by gas chromatography 
(GC) as described previously [41]. Susceptibility of lipid composition to oxidation was 
determined using an established peroxidation index (PI) as described previously [32]. In 
brief, relative contributions of the fatty acid classes were used in the formula: PI = (0.025% 
monoenoics) + (1% dienoics) + (2% trienoics) + (4% tetraenoics) + (6% pentaenoics) + (8% 
hexaenoics) [32]. 
 
Analysis of F2-isoprostanes by GC-MS 
Lipid extracts (from 15 mg tissue) were hydrolysed overnight for GC-MS analysis of F2-ISPs 
as described previously [37]. Samples were loaded onto pre-conditioned solid phase 
extraction columns (UCT CUQAX223 3 ml; United Chemical Technologies, Bristol, USA) 
and washed with 2 ml of 40 mM formic acid (pH 4.5) containing 40% (v/v) methanol and 2 
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ml hexane/MTBE (1:1). F2-isoprostanes and fatty acids were eluted from the SPE columns 
with MTBE containing 20% methanol and 1% formic acid. The F2-ISP and fatty acid fraction 
was dried down under nitrogen and derivatised with 30 µl of pentafluorobenzylbromide 
(PFBBr) (10% in acetonitrile) and 15 µl of N,N-diisopropylethylamine (DIPEA) (10% in 
acetonitrile) at 37°C for 30 min. Excess reagents were evaporated under nitrogen. The F2-ISP 
PFBenzyl ester was derivatised with 15 µl acetonitrile plus 30 µl BSTFA+1% TMCS for 1 
hour at 37°C. The derivatised samples were dried under nitrogen, reconstituted in 30 µl 
toluene and analysed using the GC-MS. Selected-reaction monitoring (SRM) was performed 
using the negative chemical ionisation (NCI) mode (70eV) with argon as the reagent gas 
(1.25 ml/min) and the collision gas (0.6 ml/min). The ion source was maintained at 150°C 
and the quadrupoles at 150°C. For F2-ISP analysis, derivatised samples (1 µl) were injected 
splitless into the GC injection port. Column temperature was increased from 180°C to 280°C 
at 40°C/min to 305°C with a final hold of 4 min. Quantification of F2-ISPs (F2αIII-ISP + 
F2αVI-ISP) was achieved by comparison of specific SRM transitions with their 
corresponding heavy isotope internal standards. 
 
Statistical analysis 
Differences between the Control and PD group fatty acids were assessed using a 2-tailed t-
test for unpaired data where P < 0.05 was considered significant. Additional post hoc 
comparisons were conducted using the method of Benjamini and Hochberg [42], these 
analyses were conducted using the p.adjust command in the package “stats” in R version 
2.15.2 (R Core Development Team)[43]. Differences in F2-ISPs were assessed in a separate 
sample using one-way ANOVA and post-hoc analysis by Fisher’s Least Significant 





Fatty acid analysis in the anterior cingulate cortex 
In the current study we compared global fatty acid profiles in the ACC and OCC. The ACC 
was used as pathological changes associated with α-syn are present from Braak stage 4 
[3,6,7,8], whereas the OCC was chosen as it is pathologically spared and serves as a region-
specific comparator [44,45]. Other regions of the brain that may be more severely affected by 
PD pathology (e.g. the SN) were avoided as accompanying loss of neuronal structures may 
potentially change fatty acid profiles due to gross alterations in cellular / tissue composition 
in PD cases as compared to control tissues. 
 
Analysis of fatty acid methyl esters by GC revealed 15 predominant lipid species. The most 
abundant fatty acids in the ACC were C16:0, C18:0 and C18:1n9. When the fatty acid levels 
were quantified and expressed per mg brain tissue, most species were significantly lower in 
the PD ACC compared to the Con ACC (Table 1). Overall fatty acid levels were 26.5% lower 
in the PD ACC compared to the Con ACC, a finding consistent with our recent data related to 
sphingolipid changes in the PD brain [36]. More importantly, in terms of assessing propensity 
to lipid peroxidation, when the fatty acids were compared in terms of their mol% distribution, 
we detected a significant change in the relative proportion of saturated and unsaturated lipids 
in the PD ACC compared to the Con ACC (Fig 1A). Notably, the relative amounts of the two 
fatty acids with the greatest degree of unsaturation (C22:5n6 an C22:6n3) were increased by 
109% and 73%, respectively (Fig 1A). As a fatty acid class, the relative concentration of 
PUFAs was increased by 33% in the PD ACC compared to the Con ACC, and this resulted in 
a significant 44% increase in the calculated PI (Fig 1B). This analysis reveals for the first 
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time that the PD ACC has a greater propensity for lipid peroxidation compared to the Con 
ACC. 
 
Fatty acid analysis in the occipital cortex 
Based on previous data showing that Lewy body pathology is associated with lipid 
peroxidation [14,46] and our recent study showing that the PD cohort used in the current 
experiments have increased levels of insoluble α-syn in the ACC [36], we also assessed the 
OCC as a comparator region that is largely devoid of pathology. The overall levels of fatty 
acids detected in the OCC were similar to the ACC (Table 2). In contrast, there was only one 
statistically significant change; levels of C16:1n7 were 22.6% lower in the PD OCC 
compared to the Con OCC (Table 2). Although fatty acid levels were not different overall, a 
trend (P = 0.07) for a 20% reduction in fatty acids in the PD OCC compared to the Con OCC 
was noted (Table 2). 
 
When the fatty acids were compared in terms of their mol% distribution, the overall profiles 
were quite similar to those observed in both the PD ACC and Con ACC samples (Figs 1A 
and 2A), however, in contrast to this similarity, there were no differences in the proportional 
distribution of fatty acids, their degree of unsaturation, or the PI values when the PD OCC 
was compared to the Con OCC (Fig 2B). This indicates that region-specific changes in global 
fatty acid profiles are associated with PD.  
 
F2-isoprostane analysis 
In order to determine whether the change in PUFA distribution and PI observed in the PD 
ACC was associated with a marker of lipid oxidation, we assessed tissue F2-ISP levels by 
GC-MS. The data indicate significant between group interactions by one-way ANOVA (P = 
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0.0003). Post-hoc analysis by Fisher’s LSD revealed a significant (P = 0.005) 72% increase 
in F2-ISP levels in the PD ACC compared to the Con ACC (Fig 3). We also detected a trend 
for an increase in OCC F2-ISP levels when the PD group was compared to the Con group (P 
= 0.053). In addition, the PD OCC F2-ISP levels were significantly (P = 0.005) lower (by 
46%) than the amount detected in the PD ACC. Overall, this indicates a significant increase 




The vast majority of brain tissue fatty acids (>95%) we have analysed herein are derived 
from membrane phospholipids. The extent of fatty acyl chain saturation is well known to 
affect membrane fluidity, and specific fatty acids have potent biological activities and/or give 
rise to biologically active molecules [35,47]. For example, arachidonic acid (C20:4n-6) is the 
precursor for prostaglandins, leukotrienes and specific hydroxy and hydroperoxy arachidonic 
acid derivatives that are potent mediators of neuroinflammation [35,48]. There is therefore no 
doubt that alterations in fatty acid saturation profile may have an impact on neurobiology at 
multiple levels in addition to regulating susceptibility to peroxidation. 
 
From a clinical perspective, some evidence suggests that diets that are high in n-3 PUFAs 
may reduce PD risk [49]. Although other studies have found that consumption of n-3 (and n-
6) PUFAs is not associated with PD risk [50]. Intriguingly, higher consumption of 
arachidonic acid was found to be correlated with increased PD risk [50]. Although it is 
possible that diets deficient in certain PUFAs may predispose towards PD, at present there is 
no clear evidence that n-3 PUFAs are reduced in the PD brain nor that dietary 
supplementation can be used to treat or prevent this disease. Indeed our data show that the 
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relative contribution of PUFAs to the total fatty acid pool is significantly increased in the PD 
ACC but not altered in the pathologically-spared OCC. Since we have recently documented 
that neuronal loss does not occur in these early Braak stage cases [51], the alterations in fatty 
acid composition we have detected are not likely to be related to neuronal loss per se. 
 
A previous study by Julien et al. used a similar approach to us in order to assess global 
changes in fatty acid profiles in postmortem PD brain tissue [52]. In that study, the temporal 
cortex was assessed. The temporal cortex is a region that is relatively spared from Lewy body 
pathology early in PD, being affected only at late stages [3,6,7,8]. The overall fatty acid 
profiles of the temporal cortex [52] were very similar to the profiles we reported herein for 
both the ACC and OCC. In the study by Julien et al., only one statistically significant change 
was detected comparing control and PD temporal cortex samples, i.e., they showed decreased 
levels of C20:4 in the PD patients [52]. Interestingly, we also found decreased levels of 
C20:4 in the PD ACC, but not the PD OCC, as compared to controls, possibly suggesting this 
is the earliest fatty acid change observed in PD. In comparing these studies, we conclude that 
the temporal cortex may have been studied at an early disease stage when the pathological 
changes have yet to affect the overall fatty acid profile of the PD cases. Another study by 
Sharon et al. reported increases in 22:4 and 22:6 fatty acids in PD frontal cortex (Brodman 
area 8) as compared to control frontal cortex [28]. This is in agreement with our data showing 
increased PUFAs in the PD ACC (and in particular increased 22:6n-3); although frontal 
neocortex preferantially accumulates α-syn only at end-stage PD [3,6,7,8]. Based on the 
available data, we speculate that changes in global fatty acid profiles may be closely linked to 
PD-associated increases in α-syn. 
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In addition to the deleterious consequences of the high PI we have detected in the PD ACC, 
specific fatty acid changes may have other biological consequences. As mentioned above, 
previous data suggests that increased dietary levels of arachidonic acid (C20:4n-6) may be 
associated with increased PD risk [50]. Arachidonic acid may be used as a substrate for the 
formation of proinflammatory eicosanoids that have been shown to play a role in PD 
neurodegeneration [53]. The increased levels of arachidonic acid we detected in the PD ACC 
may provide additional substrate for cyclooxygenase-mediated production of such 
proinflammatory eicosanoids. Also related to arachidonic acid metabolism, we found that 
levels of the lipid oxidation marker F2-ISPs were increased in the PD ACC. This is not likely 
to be due to changes in the absolute amounts of arachidonic acid as these were very similar in 
the PD ACC and Con ACC samples (Table 1). The most plausible explanation is that the PD 
ACC is under increased oxidative stress as compared to the Con ACC (and both the Con and 
PD OCC). This would be in agreement with an increased propensity for oxidative damage as 
predicted by the higher calculated PI values (Fig 1B). 
 
F2-ISPs are a useful marker of lipid oxidative damage in PD [13,54]. For example, the sum of 
F2ISPs and structurally related isofurans (also derived from arachidonic acid oxidation) was 
increased in the PD SN compared to SN from control patients or from patients with 
neurodegenerative diseases that do not affect the SN [13]. Furthermore, Fessel et al. 
previously reported that isofurans were a more sensitive lipid peroxidation marker for the PD 
SN [55], whereas Pratico et al. showed there was no difference in F2ISP levels comparing PD 
and control cerebral neocortex, i.e., a region pathologically spared until very late in PD [56]. 
We have not measured isofurans in the present work and it is therefore possible that the levels 
of lipid oxidation may have been underestimated. 
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Independent of the impact that altered fatty acid composition has on PD ACC susceptibility 
to oxidation, it is also important to consider other interactions between α-syn and fatty acids. 
Due to its apolipoprotein-like behaviour, α-syn is well known to bind to free fatty acids and 
phospholipids [57]. In particular, long chain PUFAs have been shown to associate with α-syn 
and promote its oligomerisation [57,58]. In addition, it has also been shown that α-syn can 
directly regulate neuronal PUFA levels. One example of this relationship comes from the 
dramatic drop in 22:6n-3 levels detected in brains derived from α-syn null mice as compared 
to wild type mice [28]. The data from our current study cannot be used to determine whether 
the accumulation of α-syn in the PD ACC is driven by interactions with specific PUFAs such 
as 22:6n-3 or whether, conversely, α-syn accumulation alters neuronal lipid homeostasis in 
such a way that levels of 22:6n-3 and other PUFAs are selectively increased. This is an area 
that appears to warrant further research. 
 
It is also worth considering how changes in brain fatty acid profiles may relate to lipid 
peroxidation associated with other neurodegenerative diseases. In addition to PD, lipid 
peroxidation has been reported to be associated with Alzheimer’s disease, Huntington’s 
disease, and amyotrophic lateral sclerosis [59,60,61]. Most research in this area has not 
focused on the fatty acid profiles of susceptible brain regions prior to development of severe 
pathology. The general thrust of much work in this filed has therefore been more related to 
factors such as altered energy metabolism and changes in mitochondrial function that may 
increase free radical stress in the brain (see [62], for a comprehensive review). There are 
limited data available, for example, indicating that lipid peroxidation in Alzheimer’s disease 
is associated with reduced PUFA levels [63]; however, the analysis of pathologically affected 
regions raises the possibility that altered fatty acid composition may be associated with the 
pathology rather than predisposing towards pathology. Other studies have used a lipidomics 
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approach to assess fatty acid composition in Alzheimer’s disease tissues as well as in 
subcortical ischemic vascular dementia postmortem tissues [64,65], but no strong consensus 
has been found that permits a direct comparison with the data we have presented herein. It 
would be interesting to assess fatty acid profiles in postmortem tissues derived from the 
earliest stages of these additional neurodegenerative diseases as well as to compare 
postmortem tissues from PD subjects both with and without dementia to provide further 
insights into the changes that may increase specific brain regions to lipid oxidative stress. 
 
Like all studies of human postmortem brain tissues, we acknowledge that PMI may 
contribute to the final lipid profiles we have measured. However, this is unlikely to contribute 
to the differences we detected as the PMI values were not significantly different between the 
Con and PD groups. 
 
In conclusion, we provide evidence that the global composition of fatty acids in the PD ACC 
is altered in a way that increases susceptibility to peroxidation. This has important 
implications for the eitiology of PD (and possibly other synucleinopathies), particularly as it 
relates to the PD-oxidative stress hypothesis. 
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Table 1. Anterior cingulate cortex fatty acid composition (nmol / mg tissue)	  	  
 
Control 
(n = 10) 
PD 
(n = 9) 
P-value Adjusted 
P-value 
Fatty acid mean SE mean SE   
16:0 14.96 0.51 13.95 0.72 0.259 0.299  
16:1n7 0.76 0.04 0.56 0.05 0.007  0.014  
18:0 22.51 1.08 17.69 1.51 0.017  0.024  
18:1n9 29.16 1.67 17.37 2.62 0.001  0.004  
18:1n7 5.37 0.27 3.80 0.41 0.005  0.011  
18:2n6 0.63 0.04 0.69 0.05 0.361 0.386 
20:1n9 2.86 0.28 1.25 0.28 0.001  0.004  
20:3n6 1.04 0.06 0.72 0.08 0.005  0.011  
20:4n6 6.01 0.26 6.07 0.19 0.849 0.849 
22:2n6 0.92 0.07 0.40 0.12 0.001  0.004  
22:4n6 6.43 0.31 4.73 0.52 0.011  0.018  
24:0 2.73 0.23 1.22 0.33 0.001  0.004  
22:5n6 0.58 0.06 0.86 0.09 0.018  0.024  
24:1n9 10.52 0.77 4.90 1.26 0.001  0.004  
22:6n3 6.30 0.58 7.64 0.47 0.094 0.118 
Total 112.85 5.05 82.98 8.06 0.005    
Values expressed as mean ± SE. “P-values” are derived from t-test and “Adjusted P-values” are derived 
from post hoc adjustment for multiple comparisons using the Benjamini and Hochberg approach. The 
arrows indicate direction of change for statistically significant (P<0.05) differences. PD, Parkinson’s 
disease. 
 27 
Table 2. Occipital cortex fatty acid composition (nmol / mg tissue)	  	  
 
Control 
(n = 10) 
PD 
(n = 9) 
P-value Adjusted 
P-value 
Fatty acid mean SE mean SE   
16:0 15.22 0.56 13.49 0.67 0.065 0.231  
16:1n7 0.62 0.03 0.48 0.03 0.003  0.051 
18:0 20.26 1.62 16.94 1.05 0.112 0.231 
18:1n9 22.19 3.14 15.80 1.52 0.090 0.231 
18:1n7 4.38 0.39 3.55 0.27 0.104 0.231 
18:2n6 0.83 0.05 0.79 0.06 0.629 0.674 
20:1n9 2.29 0.46 1.31 0.22 0.078 0.231 
20:3n6 0.86 0.08 0.66 0.05 0.059 0.231 
20:4n6 5.58 0.25 5.18 0.40 0.395 0.494 
22:2n6 0.52 0.15 0.30 0.07 0.215 0.309 
22:4n6 4.87 0.62 3.96 0.32 0.226 0.309 
24:0 1.74 0.52 0.87 0.16 0.139 0.231 
22:5n6 0.72 0.02 0.69 0.03 0.467 0.539 
24:1n9 7.46 1.74 4.33 0.77 0.125 0.231 
22:6n3 9.25 0.80 9.14 0.59 0.919 0.919 
Total 98.37 8.85 78.63 4.61 0.073  
Values expressed as mean ± SE. “P-values” are derived from t-test and “Adjusted P-values” are derived 
from post hoc adjustment for multiple comparisons using the Benjamini and Hochberg approach. The 





Figure 1. Comparison of fatty acyl chain structures in control and PD brain samples. 
Control (n = 10) and PD (n = 9) tissues were collected from the anterior cingulate cortex 
(ACC) and lipids were extracted, the fatty acid fraction was methylated, and the fatty acid 
methyl esters were quantified using GC analysis and comparison to internal standards. The 
data indicates the relative percentage (mol%) composition that each of the indicated fatty acyl 
chain structures contributes to the global fatty acid molecular species profile (A). The relative 
proportion of saturated (SFA), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty 
acids is also provided along with a further breakdown of the data to reflect changes in n-6 and 
n-3 PUFA composition (B). The peroxidation index (PI) reflects the theoretical susceptibility 
of the tissue oxidation (B). Control samples are indicated by the grey bars and PD samples 
are indicated by the black bars. Values are mean ± SE. ** P < 0.01 using t-test. Values above 
bars indicate % change. All results remained significant when adjusting for multiple 
comparisons using the Benjamini and Hochberg method. 
 
Figure 2. Comparison of fatty acyl chain structures in control and PD brain samples. 
Control (n = 10) and PD (n = 9) tissues were collected from the occipital cortex (OCC) and 
lipids were extracted, the fatty acid fraction was methylated, and the fatty acid methyl esters 
were quantified using GC analysis and comparison to internal standards. The data indicates 
the relative percentage (mol%) composition that each of the indicated fatty acyl chain 
structures contributes to the global fatty acid molecular species profile (A). The relative 
proportion of saturated (SFA), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty 
acids is also provided along with a further breakdown of the data to reflect changes in n-6 and 
n-3 PUFA composition (B). The peroxidation index (PI) reflects the theoretical susceptibility 
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of the tissue oxidation (B). Control samples are indicated by the grey bars and PD samples 
are indicated by the black bars. Values are mean ± SE. 
 
Figure 3. Comparison of F2-isoprostane levels in control and PD brain samples. Control 
(n = 10) and PD (n = 9) tissues were collected from the anterior cingulate cortex (ACC) and 
lipids were extracted, the F2-isoprostane fraction was purified by solid phase extraction. F2-
isoprostane PFBenzyl esters were prepared and derivatised with BSTFA and TMCS for 
analysis using GC-MS. The F2-isoprostane quantified by comparison to internal standards. 
Data are expressed as ng F2-isoprostane per g of tissue. Control samples are indicated by the 
grey bars and PD samples are indicated by the black bars. Values are mean ± SE. Values 
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